Multimerin-1 (MMRN1) as novel adverse marker in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Robert B. Gerbing, Yi Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Purpose: Exploratory gene expression array analyses suggested multimerin-1 (MMRN1) to be a predictive biomarker in acute myelogenous leukemia (AML). Following up on these studies, we evaluated the role of MMRN1 expression as outcome predictor in two recent Children's Oncology Group trials. Experimental Design: We retrospectively quantified MMRN1 expression in 183 participants of AAML03P1 and 750 participants of AAML0531 by reverse-transcriptase PCR and correlated expression levels with disease characteristics and clinical outcome. Results: In AAML03P1, the highest quartile of MMRN1 expression (expression ≥0.5 relative to b-glucuronidase; n = 45) was associated with inferior event-free survival (EFS; P < 0.002) and higher relapse risk (P < 0.004). In AAML0531, in which we quantified MMRN1 mRNA for validation, patients with relative MMRN1 expression ≥0.5 (n=160) less likely achieved remission (67% vs. 77%, P = 0.006), and more frequently had minimal residual disease (43% vs. 24%, P = 0.001) after one induction course. They had inferior overall survival (OS; 44% ± 9% vs. 69% ± 4% at 5 years; P < 0.001) and EFS (32% ± 8% vs. 54% ± 4% at 5 years; P < 0.001) and higher relapse risk (57% ± 10% vs. 35% ± 5% at 5 years; P < 0.001). These differences were partly attributable to the fact that patients with high MMRN1 expression less likely had cytogenetic/molecular low-risk disease (P < 0.001) than those with low MMRN1 expression. Nevertheless, after multivariable adjustment, high MMRN1 expression remained statistically significantly associated with shorter OS (HR, 1.57; 95% confidence interval, 1.17-2.12; P = 0.003) and EFS (HR, 1.34; 1.04-1.73; P = 0.025), and higher relapse risk (HR, 1.40; 1.01-1.94; P = 0.044). Conclusions: Together, our studies identify MMRN1 expression as a novel biomarker that may refine AML risk stratification.

Original languageEnglish (US)
Pages (from-to)3187-3195
Number of pages9
JournalClinical Cancer Research
Volume21
Issue number14
DOIs
StatePublished - Jul 15 2015

Bibliographical note

Publisher Copyright:
© 2015 American Association for Cancer Research.

Fingerprint

Dive into the research topics of 'Multimerin-1 (MMRN1) as novel adverse marker in pediatric acute myeloid leukemia: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this